Sanofi bets on Sino Biopharm’s transplant drug in $1.5bn licensing deal
Sanofi has taken a chance on Sino Biopharmaceutical’s first-in-class, anti-inflammatory and anti-fibrotic asset, rovadicitinib, through a licensing agreement worth up…
04 Mar 2026
Aspire Biopharma and Microsize collaborate for alprazolam powder formulation
Aspire Biopharma has entered a strategic partnership with Microsize to advance the development of a new sublingual powder formulation of alprazolam, targeting rapid anxiety relief. Alprazolam is the active pharmaceutical…
04 Mar 2026
Esperion to acquire Corstasis for cardiovascular franchise expansion
Esperion Therapeutics has signed a definitive agreement to acquire Corstasis Therapeutics to expand its cardiovascular franchise with the addition of Enbumyst, a bumetanide nasal spray. Enbumyst is approved by the…
03 Mar 2026
OSE narrows pipeline focus amid Boehringer MASH collaboration retreat
French biotech OSE Therapeutics has shifted focus to its later-stage clinical assets as it looks to prioritise near-term value creation. OSE’s pipeline rejig comes as Boehringer Ingelheim relinquishes its stake…
03 Mar 2026
Pharma rings the changes as CEO shake-up continues
Bavarian Nordic’s announcement that Paul Chaplin will step down as CEO has marked the latest high-profile change at a pharmaceutical company in 2026. Chaplin, who has been at the helm…
03 Mar 2026
Rallybio to acquire Candid Therapeutics
US-based biotechnology company Rallybio has entered a definitive agreement to acquire Candid Therapeutics through a merger transaction. Following completion, the combined entity will operate as Candid Therapeutics and list on…
03 Mar 2026
Novo Nordisk starts €432m Ireland facility upgrade for oral Wegovy production
Novo Nordisk has invested €432m ($501m) to upgrade its facility in Ireland to ensure the drugmaker can meet the anticipated high demand for oral weight loss drugs. Novo’s site in…